Efficacy Shown for New Melanoma Therapeutic Vaccine
By Physician’s Briefing Staff HealthDay Reporter
FRIDAY, Dec. 15, 2023 -- In a recent trial, a new melanoma vaccine, mRNA-4157 (V940), when taken in combination with Keytruda (pembrolizumab), was found to be effective in battling the deadly skin cancer.
People with advanced melanomas who received the vaccine plus Merck's cancer drug Keytruda were 49 percent less likely to die or have their cancer return after three years than those who were given only Keytruda, vaccine maker Moderna Inc. announced Friday.
"Importantly for this technology, the... study was the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial and the first combination therapy to show a significant benefit over Keytruda alone in adjuvant melanoma," Moderna Senior Vice President Kyle Holen, M.D., said in a company news release. "We look forward to sharing these data with people impacted by this disease and the broader scientific community."
The findings are based on an ongoing randomized trial involving 157 patients with high-risk stage 3/4 melanoma who first had surgery to completely remove cancerous growths. Patients received 1 mg of the mRNA vaccine every three weeks for a total of nine doses, along with 200 mg of Keytruda every three weeks for about a year. Their outcomes were compared to those using Keytruda alone for approximately a year.
The companies have already begun phase 3 trials of the vaccine-drug combo, and the U.S. Food and Drug Administration has designated the treatment as a breakthrough therapy to speed its development and review.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Delayed Melanoma Care During Pandemic Proved Costly
TUESDAY, Feb. 27, 2024 -- Delays in melanoma diagnoses due to COVID-19 pandemic lockdowns were associated with a significant burden, including years of life lost and costs...
Amtagvi Approved by the FDA for Treatment of Advanced Melanoma
TUESDAY, Feb. 20, 2024 -- Amtagvi (lifileucel) has been approved by the U.S. Food and Drug Administration for the treatment of advanced melanoma. Amtagvi becomes the first...
Smoking Linked to Melanoma-Associated Death in Early-Stage Melanoma
MONDAY, Feb. 12, 2024 -- For patients with clinical stage I and II melanoma, smoking is associated with an increased risk for melanoma-associated death, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.